Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma

Journal of Hepatology

Volumn 51, Issue 5, 2009, Pages 890-897

  Wu, Jaw Ching ^a,b   Huang, Yi Hsiang ^a,b   Chau, Gar Yang ^a,b   Su, Chien Wei ^a,b   Lai, Chung Ru ^a   Lee, Pui Ching ^a   Huo, Teh Ia ^a,b   Sheen, I Jane ^b   Lee, Shou Dong ^a,b   Lui, Wing Yiu ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Genotype; Hepatic inflammatory activity; Hepatitis B viral load; Hepatocellular carcinoma; Late recurrence

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; TAIWAN; TIME FACTORS; VIRAL LOAD;

EID: 70349741318     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.07.009     Document Type: Article

References (40)

1. El-Serag H.B., Marrero J.A., Rudolph L., and Reddy K.R. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134 (2008) 1752-1763
2. Llovet J.M., and Bruix J. Novel advancement in the management of hepatocellular carcinoma in 2008. J Hepatol 48 Suppl. 1 (2008) S20-S37
3. Huo T.I., Lin H.C., Hsia C.Y., Wu J.C., Lee P.C., Chi C.W., et al. The model for end-stage liver disease based cancer staging systems are better prognostic models for hepatocellular carcinoma: a prospective sequential survey. Am J Gastroenterol 102 (2007) 1920-1930
4. Huang Y.H., Chen C.H., Chang T.T., Chen S.C., Wang S.Y., Lee P.C., et al. The role of transcatheter arterial embolization in patients with resectable hepatocellular carcinoma: a nation-wide, multicenter study. Liver Int 24 (2004) 419-424
5. Lopez P.M., Villanueva A., and Llovet J.M. Systemic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23 (2006) 1535-1547
6. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., et al. Gene expression in fixed tissues and outcomes in hepatocellular carcinoma. N Eng J Med 359 (2008) 1995-2004
7. Imamura H., Matsuyama Y., Tanaka E., Ohkubo T., Hasegawa K., Miyagawa S., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38 (2003) 200-207
8. Portolani N., Coniglio A., Ghidoni S., Giovanelli M., Benetti A., Tiberio G.A., et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 243 (2006) 229-235
9. Ishizawa T., Hasegawa K., Aoki T., Takahashi M., Inoue Y., Sano K., et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 134 (2008) 1908-1916
10. Hasegawa K., Makuuchi M., Takayama T., Kokudo N., Arii S., Okazaki M., et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 49 (2008) 589-594
11. Norder H., Courouce A.M., and Magnius L.O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 198 (1994) 489-503
12. Hoofnagle J.H., Doo E., Liang J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
13. Huang Y.H., Wu J.C., Chang T.T., Sheen I.J., Lee P.C., Huo T.I., et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 10 (2003) 277-284
14. Su C.W., Huang Y.H., Huo T.I., Shih H.H., Sheen I.J., Chen S.W., et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 135 (2006) 1625-1635
15. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118 (2000) 554-559
16. Chu C.J., Hussain M., and Lok A.S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122 (2002) 1756-1762
17. Keeffe E.B., Dieterich D.T., Han S.H., Jacobson I.M., Martin P., Schiff E.R., et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 6 (2008) 1315-1341
18. Chan H.L., Tse C.H., Mo F., Koh J., Wong V.W., Wong G.L., et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26 (2008) 177-182
19. Yang H.I., Yeh S.H., Chen P.J., Iioeje U.H., Jen C.L., Su J., et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100 (2008) 1134-1143
20. Okamoto H., Tsuda F., Akahane Y., Sugai Y., Yoshiba M., Moriyama K., et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 68 (1994) 8102-8110
21. Buckwold V.E., Xu Z., Chen M., Yen T.S., and Ou J.H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 70 (1996) 5845-5851
22. Kao J.H., Chen P.J., Lai M.Y., and Chen D.S. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124 (2003) 327-334
23. Yuen M.F., Tanaka Y., Mizokami M., Yuen J.C., Wong D.K., Yuan H.J., et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogen 25 (2004) 1593-1598
24. Chen Y.J., Yeh S.H., Chen J.T., Wu C.C., Hsu M.T., Tsai S.F., et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119 (2000) 431-440
25. Ishak K., Baptista A., Bianchi L., Callea F., DeGroote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
26. Wu J.C., Chen C.L., Hou M.C., Chen T.Z., Lee S.D., and Lo K.J. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitation of the polymerase chain reaction. Hepatology 19 (1994) 836-840
27. Kwok S., and Higuchi R. Avoiding false positives with PCR. Nature 339 (1989) 237-238
28. Mizokami M., Nakano T., Orito E., Tanaka Y., Sakugawa H., Mukaide M., et al. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 450 (1999) 66-71
29. Yotsumoto S., Kojima M., Shoji I., Yamamoto K., Okamoto H., and Mishiro S. Fulminant hepatitis related to transmission of hepatitis B variants with precore mutations between spouses. Hepatology 16 (1992) 31-35
30. Chan H.L., Hussain M., and Lok A.S. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 29 (1999) 976-984
31. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35 (2001) 421-430
32. Batts K.P., and Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 19 (1995) 1409-1417
33. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
34. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
35. Mazzaferro V., Romito R., Schiavo M., Mariani L., Camerini T., Bhoori S., et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44 (2006) 1543-1554
36. Orito E., Mizokami M., Sakugawa H., Michitaka K., Ishikawa K., Ichida T., et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 33 (2001) 218-223
37. Chan H.L., Tsang S.W., Liew C.T., Tse C.H., Wong M.L., Ching J.Y., et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 97 (2002) 406-412
38. Huang Y.H., Wu J.C., Chang T.T., Sheen I.J., Huo T.I., Lee P.C., et al. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients. J Viral Hepat 13 (2006) 336-342
39. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 (2005) 1208-1236
40. Imamura H., Sano K., Sugawara Y., Kokudo N., and Makuuchi M. Assessment of hepatic reserve for indication of hepatic resection: decision tree incorporating indocyanine green test. J Hepatobiliary Pancreat Surg 12 (2005) 16-22